The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provide
The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
대표청구항▼
1. A pharmaceutical composition comprising a compound having the following formula: or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient;wherein:(i) Z1 and Z2 are —OR.(ii) Z1 and Z2 taken together with the boron atom form a 5- to 8—membered ring having at least
1. A pharmaceutical composition comprising a compound having the following formula: or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient;wherein:(i) Z1 and Z2 are —OR.(ii) Z1 and Z2 taken together with the boron atom form a 5- to 8—membered ring having at least one O atom directly attached to the boron, wherein the ring is comprised of carbon atoms and optionally one or more additional heteroatoms independently selected from the group consisting of N, S, and O, wherein the 5- to 8—membered ring is optionally substituted with one or more C1-6 aliphatic group;each R is hydrogen or an optionally substituted C1-6 aliphatic or, C6-12 aryl group;X is a (CH2)1-6 wherein one methylene unit of X is replaced with —O— and X is attached to the para position of the phenyl group relative to the boron atom;each occurrence of R1 is, independently, halogen, —OR, —CF3, —CN, —NO2, —NC, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R′)2, —CHO, —N3, —N2R, —N(R′)2, —B(OH)2, or an optionally substituted C1-8 aliphatic group;each instance of R2 is, independently, halogen, —OR, —CF3, —NO2, —NC, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R′)2, —N2R, —N(R′)2, an optionally substituted C1-8 aliphatic or C6-12 aryl group;wherein each R′ is hydrogen, —C(O)R, or an optionally substituted C1-6 aliphatic group; andeach instance of n and m is, independently, 0 to 4. 2. The pharmaceutical composition of claim 1, wherein Z1 is —OR and Z2 is —OR. 3. The pharmaceutical composition of claim 1, wherein R1 is halogen. 4. The pharmaceutical composition of claim 1, wherein at least one R1 group is fluoro in the ortho position relative to the boron atom. 5. The pharmaceutical composition of claim 1, wherein X is —O—. 6. The pharmaceutical composition of claim 1, wherein n is 1. 7. The pharmaceutical composition of claim 1, wherein m is 0. 8. The pharmaceutical composition of claim 1, wherein the compound has the following formula: or a pharmaceutically acceptable form thereof. 9. A compound having the following formula: or a pharmaceutically acceptable form thereof. 10. The compound of claim 9, wherein the compound has the following formula: or a pharmaceutically acceptable form thereof. 11. A method for treating a fatty acid amide hydrolase (FAAH) mediated disorder comprising administering to a subject having the FAAH mediated disorder a therapeutically effective amount of a compound having the following formula: or a pharmaceutically acceptable form thereof; wherein:(i) Z1 and Z2 are —OR; or(ii) Z1 and Z2 taken together with the boron atom form a 5- to 8—membered ring having at least one O atom directly attached to the boron, wherein the ring is comprised of carbon atoms and optionally one or more additional heteroatoms independently selected from the group consisting of N, S, and O, wherein the 5- to 8—membered ring is optionally substituted with one or more C1-6 aliphatic group;each R is hydrogen or an optionally substituted C1-6 aliphatic, or C6-12 aryl group;X is a (CH2)1-6 wherein one methylene unit of X is replaced with —O— and X is attached to the para position of the phenyl group relative to the boron atom;each occurrence of R1 is, independently, halogen, —OR, —CF3, —CN, —NO2, —NC, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R′)2, —CHO, —N3, —N2R, —N(R′)2, —B(OH)2, or an optionally substituted C1-8 aliphatic group;each instance of R2 is, independently, halogen, —OR, —CF3, —NO2, —NC, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R′)2, —N3, —N2R, —N(R′)2, an optionally substituted C1-8 aliphatic or C6-12 aryl group;wherein each R′ is hydrogen, —C(O)R, or an optionally substituted C1-6 aliphatic group; andeach instance of n and m is, independently, 0 to 4;wherein the FAAH-mediated disorder is a painful syndrome, disease, or disorder. 12. The method of claim 11, wherein the compound has the following formula: or a pharmaceutically acceptable form thereof. 13. The method of claim 12, wherein the compound has the following formula: or a pharmaceutically acceptable form thereof. 14. The method of claim 11, wherein the painful syndrome, disease, or disorder is selected from a group consisting of neuropathic pain; peripheral neuropathic pain; central pain; deafferentation pain; chronic pain; post-operative pain; chronic nociceptive pain; acute pain; phantom pain; transient acute pain; non-inflammatory pain; inflammatory pain; pain associated with cancer; preoperative pain; arthritic pain; lumbosacral pain; musculo-skeletal pain; headache; migraine; muscle ache; lower back or neck pain; and toothache. 15. The method of claim 14, wherein the painful syndrome, disease, or disorder is neuropathic pain selected from a group consisting of diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins, or chronic inflammatory conditions. 16. The method of claim 11, wherein the painful syndrome, disease, or disorder is post-herpetic neuralgia. 17. The method of claim 12, wherein the painful syndrome, disease, or disorder is post-herpetic neuralgia. 18. The method of claim 13, wherein the painful syndrome, disease, or disorder is post-herpetic neuralgia
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (91)
Barnes Keith D. ; Hu Yulin, 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents.
Bezborodov Vladimir S. (Minsk SUX) Grinkevich Oleg A. (Minsk SUX) Grebenkin Mikhail F. (Moscow SUX) Lapanik Valery I. (Minsk SUX) Minko Anatoly A. (Minsk SUX) Rzhussky Vitaly V. (Minsk SUX) Muravsky , 2-(4,3-Disubstituted phenyl)-5-alkyl-1,3,2-dioxaborinane derivatives and liquid crystal material.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lou,Rongliang; Zhou,Jiacheng; Bhattacharjee,Ashoke; Chen,Shili; Chen,Yi; Farmer,Jay J.; Goldberg,Joel A.; Hanselmann,Roger; Orbin,Alia; Oyelere,Adegboyega K.; Salvino,Joseph M.; Springer,Dane M.; Tra, Biaryl heterocyclic compounds and methods of making and using the same.
Cavezzan Jacques (Villeurbanne FRX) Priou Christian (Villeurbanne FRX), Cationically crosslinkable polyorganosiloxanes and antiadhesive coatings produced therefrom.
Gray George W. (Cottingham GB3) Hird Michael (Hull GB3) Lacey David (Hull GB3) Toyne Kenneth J. (Hull GB3) Reiffenrath Volker (Rossdorf DEX) Wchtler Andreas (Griesheim DEX) Krause Joachim (Dieburg DE, Fluorinated oligophenyls and their use in liquid crystal materials.
Priou Christian (Villeurbanne FRX), Initators for the cationic crosslinking of polymers containing organofunctional groups, crosslinkable polyorganosiloxane.
Wand,Michael D.; More,Kundalika M.; Thurmes,William N., Liquid crystal compositions comprising an organogermanium compound and methods for using the same.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Benson Bradley J. (Chapel Hill NC) Chen Xiannong (Athens GA) Cianciolo George J. (Chapel Hill NC) Diaz Jose-Luis (Durham NC) Ishaq Khalid S. (Chapel Hill NC) Morris-Natschke Susan L. (Apex NC) Uhing , N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cyto.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Frances, Jean-Marc; Gambut, Lucille, Plastic material surface treatment with a polymerizable and/or crosslinkable organic composition having reactive functions.
Schlosser Hubert (Glashutten/Taunus DEX) Wingen Rainer (Hattersheim/Main DEX) Manero Javier (Frankfurt am Main DEX), Process for cross-coupling aromatic boronic acids with aromatic halogen compounds or perfluoroalkylsulfonates.
Butlin, Margaret Anne; Butlin, Roger John; Hogan, Philip John; Meudt, Andreas, Protected forms of N-(3-methoxy-5-methylpiperazin-2-yl)-2-(4-[1,3,4,-oxadiazol-2-yl]phenyl)-pyridine-3-sulphonamide.
Barker Andrew J. (Macclesfield GB2) Hughes Leslie R. (Macclesfield GB2) Marsham Peter R. (Poynton GB2) Oldfield John (Wilmslow GB2) Pegg Stephen J. (Macclesfield GB2), Quinazoline derivatives possessing anti-tumor activity.
Reiffenrath Volker (Rossdorf) Krause Joachim (Dieburg) Wchtler Andreas (Griesheim) Geelhaar Thomas (Mainz DEX) Coates David (Wimborne GBX) Sage Ian (Broadstone GBX) Greenfield Simon (Poole GBX), Smectic liquid-crystal medium.
Priou Christian ; Soldat Andre,FRX ; Kerr ; III Stuart R. ; Beaty Reeshemah, Stable polyorganosiloxane based compositions with cross-linkable functional groups and their use for producing antiadhesive coating.
Bach Nicholas James ; Draheim Susan Elizabeth ; Dillard Robert Delane ; Mihelich Edward David ; Sawyer Jason Scott ; Beight Douglas Wade ; Phillips Michael LeRoy ; Suarez Tulio ; Sall Daniel Jon ; Ba, Substituted tricyclics.
Fuss Robert Walter,DEX ; Manero Javier,DEX ; Schlosser Hubert,DEX ; Wingen Rainer,DEX, Thiadiazole derivatives, process for their preparation, and their use as precursors for the production of liquid crystal.
Hudson Derek (San Anselmo CA) Johnson Charles R. (Berkeley CA) Ross Michael J. (Hillsborough CA) Shoemaker Kevin R. (San Francisco CA) Cass Robert T. (San Mateo CA) Giebel Lutz B. (Burlingame CA), Thin film HPMP matrix systems and methods for constructing and displaying ligands.
Marie-Christine Cotting FR; Gerard Joubert FR; Olivier Loubet FR, Use of silicone compositions cross-linkable by cationic process under UV radiation and of an onium borate type photoinitiator for coating flat joints, particularly cylinder head gaskets.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.